Abstract
Purpose
There is a lack of studies to show localization of botulinum toxins (BoNT) within bladder wall and/or absorption rates. Our study examined the later distribution of BoNTA/gadolinium within the bladder wall by performing a delayed MRI scan after intravesical injection. This potentially may help to explain the level and mechanism at which BoNT may be producing its effect.
Methods
A prospective study enrolled 20 consecutive patients with neuropathic or idiopathic overactive bladders. The Aim of the study was to perform MRI 3 h post procedure. Botox 100–200 IU was reconstituted with 19 ml saline and 1 ml of gadolinium contrast. Intradetrusor injections were administered using a rigid 21F cystoscope with a total of 20 injections into bladder wall, including two into the trigone. The depth of injection was approximately 2 mm, without raising a bleb. One radiologist reviewed films and reported on the number of bladder walls with contrast, location, the presence of extravesical extravasation, contrast in distal ureter(s), and bladder wall thickness.
Results
Ninety percentage of patients had contrast within bladder wall. There was a variation in the number of bladder walls involved; 85 % had contrast seen in at least two walls. Also, a variation was noted in the extent of extravasation; 80 % showed some evidence.
Conclusions
Diffusion of BoNT after intravesical injection is very common once bladder wall is breeched. Precise injection localization into muscle layer may not be as relevant to outcome as previously assumed. The assumption in our study that localization and diffusion of contrast also represents the localization of BoNT is open to critique as BoNT diffusion is potentially slower (Mehnert et al. in World J Urol 27(3):397–403, 2009). The absence of systemic symptoms after the injection in our series supports guidelines concerning the safety of procedure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Patel AK, Patterson JM, Chapple CR (2006) Botulinum toxin injections for neurogenic and idiopathic detrusor overactivity: a critical analysis of results. Eur Urol 50(4):684–709
Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697
Apostolidis A, Dasgupta P, Denys P et al (2009) Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol 55(1):100–119
Schmid DM, Sauermann P, Werner M et al (2006) Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176(1):177–185
Mehnert U, Boy S, Schmid M et al (2009) A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 27(3):397–403
Kuo HC (2007) Comparison of effectiveness of detrusor suburothelial and bladder base injections of botulinum toxin A for idiopathic detrusor overactivity. J Urol 178:1359–1363
Hakenberg OW, Linne C, Manseck A, Wirth MP (2000) Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn 19(5):585–593
Rule AD, St Sauver JL, Jacobson DJ et al (2009) Three-dimensional ultrasound bladder characteristics and their association with prostate size and lower urinary tract dysfunction among men in the community. Urology 74(4):908–913
Apostolidis A, Dasgupta P, Fowler CJ (2006) Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol 49(4):644–650
Brady CM, Apostolidis A, Harper M et al (2004) Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity (NDO) following intravesical resiniferatoxin treatment. BJU Int 93:770–776
Brady C, Apostolidis A, Yiangou Y et al (2004) P2X3-immunoreactive nerve fibres in neurogenic detrusor overactivity and the effect of intravesical resiniferatoxin (RTX). Eur Urol 46:247–253
Coelho A, Cruz F, Cruz CD, Avelino A (2012) Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol 61(6):1178–1184
Kuo HC (2005) Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66:94–98
Chapple CR (2012) Which preparation of botulinum toxin A should be used, where should it be injected, and how should its efficacy be assessed? Eur Urol 61(5):936–937
Manecksha RP, Cullen IM, Ahmad S et al (2012) Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61(5):928–935
Dykstra DD, Sidi AA (1990) Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil 71:24–26
Wyndaele JJ, van Dromme SA (2002) Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 40:599–600
De Laet K, Wyndaele JJ (2005) Adverse events after botulinumA toxin injection for neurogenic voiding disorders. Spinal Cord 43:397–399
Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P (2006) What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97:1030–1034
Del Popolo G, Filocamo MT, Li Marzi V et al (2008) Neurogenic detrusor overactivity treated with English botulinum toxin A: 8-year experience of one single centre. Eur Urol 53:1013–1019
Acknowledgments
The authors acknowledge Emer Doyle and other MRI department radiographers for their assistance with MRI imaging.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alsinnawi, M., Torreggiani, W., Sheikh, M. et al. Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection. Int Urol Nephrol 47, 893–898 (2015). https://doi.org/10.1007/s11255-015-0976-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-015-0976-2